Founded in January 2011, CALIXAR currently employs 15 skilled people (including 9 PhDs).

CALIXAR’s approach allows to preserve the original structure and function of membrane proteins (GPCRs, Ion Channels, Transporters, Receptors, Anchors and Viral Proteins) providing solutions for pharmaceutical industries, biotechnology companies and academic teams to develop conformational antibodies, formulate new vaccines, carry out Structure Based Drug Discovery and/or HTS assays. Moreover, the expertise is also specifically adapted to downstream processing (DSP) as well as upstream processing (USP – expression part).


  • Membrane proteins represent more than 60% of all therapeutic targets. However only 1 percent of the 3D structures were solved mainly with mutations…
  • The real challenge with membrane proteins is to produce and isolate them in a native conformation without mutations or deletions and with high purity in solution.
  • Conventional approaches tend to affect the membrane proteins integrity forcing researchers to use bypass methods such as refolding or mutagenesis or not enough pure scaffolds systems.

MP Chart diagram


To overcome this crucial issue, our company develops new tools and protocols for the deorphanization, identification, expression, extraction, purification, stabilization, structural functional characterization, crystallization of membrane proteins as well as detergent quantification. The starting biological material (virus, bacteria, primary cells, organs,…) can be endogenous or recombinant systems. CALIXAR uses original, innovative and customized chemistry that aims to adapt to the biochemical characteristics of the target during the solubilization/ purification/stabilization steps.

Calixar Team – Lyon, June 2017

Calixar Team – Lyon, June 2017

Calixar Team – Lyon, June 2017

Chem2Stab Team – Avignon, April 2017


CALIXAR’s team is led by corporate values
commitment, perseverance and humanism for best performances and excellence in innovation